Medical technology company Inspire Medical Systems (NYSE: INSP) announced better-than-expected revenue in Q1 CY2026, with sales up 1.6% year on year to $204.6 million. On the other hand, the company’s full-year revenue guidance of $850 million at the midpoint came in 11.6% below analysts’ estimates. Its non-GAAP profit of $0.10 per share was significantly above analysts’ consensus estimates.
Is now the time to buy INSP? Find out in our full research report (it’s free for active Edge members).
Inspire Medical Systems (INSP) Q1 CY2026 Highlights:
- Revenue: $204.6 million vs analyst estimates of $200.7 million (1.6% year-on-year growth, 1.9% beat)
- Adjusted EPS: $0.10 vs analyst estimates of -$0.26 (significant beat)
- Adjusted EBITDA: $35.89 million vs analyst estimates of $19.86 million (17.5% margin, 80.7% beat)
- The company dropped its revenue guidance for the full year to $850 million at the midpoint from $975 million, a 12.8% decrease
- Management lowered its full-year Adjusted EPS guidance to $1 at the midpoint, a 52.4% decrease
- Operating Margin: -0.5%, in line with the same quarter last year
- Market Capitalization: $1.58 billion
StockStory’s Take
Inspire Medical Systems’ first quarter results were met with a significant negative response from the market, as management pointed to persistent challenges in reimbursement coding and operational disruptions related to the WISER program. CEO Timothy Herbert described the period as one of uncertainty, highlighting that both the ongoing reimbursement confusion and new prior authorization requirements in six WISER pilot states materially impacted the company’s revenue pipeline. These factors led to a cautious stance on short-term performance, with Herbert acknowledging that many treatment centers put on the brakes to understand new billing protocols before proceeding with patient authorizations. Additionally, management revised its full-year revenue guidance to a range of $825 million to $875 million, down from its prior range, reflecting anticipated challenges for the remainder of the year. The full-year adjusted diluted EPS guidance was also revised to a range of $0.75 to $1.25.
Looking ahead, Inspire Medical Systems’ forward guidance is shaped by expectations of continued reimbursement hurdles and delays stemming from the WISER program, with management emphasizing that near-term growth depends on resolving these bottlenecks. Herbert explained that the company's outlook relies on gradually building centers’ confidence in coding and reimbursement and improving prior authorizations as the year progresses. The company is prioritizing educational outreach and support for treatment centers, aiming for gradual improvement in procedural volumes as centers gain experience with new coding practices.
Key Insights from Management’s Remarks
Management attributed the quarter’s performance to a combination of external reimbursement challenges, internal territory adjustments, and the impact of government policy changes, while also spotlighting progress in product adoption and clinical evidence generation.
- Reimbursement coding disruptions: Persistent uncertainty around coding for the Inspire V device led many treatment centers to slow or pause patient authorizations, adversely affecting new procedures and revenue growth during the quarter.
- WISER program headwinds: The implementation of the WISER initiative, requiring AI-reviewed prior authorizations for Medicare cases in six states, introduced procedural delays and administrative hurdles, which management identified as a significant revenue headwind.
- Territory and salesforce realignment: Inspire undertook a strategic consolidation of U.S. territories and increased its field clinical representatives to achieve a one-to-one ratio with territory managers. Management described this as a purposeful move to better support centers navigating reimbursement complexities.
- Product mix stability and inventory: The shift to the Inspire V system remained stable, with the company maintaining inventory of Inspire IV devices for centers preferring clear reimbursement pathways. Management observed that once a center transitions to Inspire V, it typically remains there, provided reimbursement is reliable.
- Clinical evidence and trials: Management noted the completion of large-scale clinical studies, including the ADHERE real-world outcomes trial and the Singapore Inspire V trial, with forthcoming data presentations at the SLEEP conference expected to reinforce the therapy’s clinical value and support future adoption. The timing of these trial completions was not specified as occurring during the quarter.
Drivers of Future Performance
Inspire Medical Systems anticipates ongoing headwinds from reimbursement processes and procedural delays, while focusing on operational improvements and education to stabilize performance.
- Resolution of coding and reimbursement: The speed at which treatment centers adapt to new coding methodologies and gain confidence in billing will determine the pace of recovery. Management expects gradual improvement in prior authorizations as educational outreach and experience accumulate.
- WISER program adaptation: The company’s ability to streamline AI-reviewed prior authorizations in WISER states is critical. Management believes that as centers and staff gain familiarity with the new systems, procedural delays should abate in the second half of the year.
- Competitive and market dynamics: Although coding confusion is the immediate focus, management acknowledged that the uptake of GLP-1 weight loss medications and potential competitive device launches could influence patient flow and demand, though their current impact is difficult to quantify.
Catalysts in Upcoming Quarters
In upcoming quarters, key areas to monitor include (1) the pace at which treatment centers become comfortable with new coding and reimbursement protocols, (2) the company’s success in reducing WISER program–related procedural delays, and (3) the outcome and industry reception of new clinical data presented at the SLEEP conference. Continued monitoring of territory management effectiveness and the competitive landscape will also be crucial.
Inspire Medical Systems currently trades at $45.83, down from $54.84 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free).
Our Favorite Stocks Right Now
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren't just high-quality businesses. Something is happening with them right now. Elite fundamentals meeting near-term momentum - both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week's Strong Momentum stocks - FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
